CN121045220A - Janus激酶抑制剂的晶体形式 - Google Patents

Janus激酶抑制剂的晶体形式

Info

Publication number
CN121045220A
CN121045220A CN202511159370.4A CN202511159370A CN121045220A CN 121045220 A CN121045220 A CN 121045220A CN 202511159370 A CN202511159370 A CN 202511159370A CN 121045220 A CN121045220 A CN 121045220A
Authority
CN
China
Prior art keywords
compound
crystalline form
added
crystalline
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511159370.4A
Other languages
English (en)
Chinese (zh)
Inventor
神谷幸宏
下山典昭
大仓隆平
野路悟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CN121045220A publication Critical patent/CN121045220A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202511159370.4A 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式 Pending CN121045220A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor
CN201780086980.3A CN110325536A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780086980.3A Division CN110325536A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Publications (1)

Publication Number Publication Date
CN121045220A true CN121045220A (zh) 2025-12-02

Family

ID=60991475

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511159370.4A Pending CN121045220A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式
CN201780086980.3A Pending CN110325536A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780086980.3A Pending CN110325536A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Country Status (13)

Country Link
US (1) US11339181B2 (https=)
EP (1) EP3559003B1 (https=)
JP (3) JP2020502224A (https=)
KR (1) KR102788829B1 (https=)
CN (2) CN121045220A (https=)
AU (1) AU2017380213B2 (https=)
BR (1) BR112019012210A2 (https=)
CA (1) CA3044771A1 (https=)
ES (1) ES2926986T3 (https=)
IL (1) IL267393B2 (https=)
MX (1) MX386181B (https=)
TW (1) TWI822666B (https=)
WO (1) WO2018117153A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012688A2 (pt) 2016-12-21 2019-11-19 Japan Tobacco Inc método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
JP7807247B2 (ja) * 2021-02-05 2026-01-27 ロート製薬株式会社 シェーグレン症候群治療剤
US20250041304A1 (en) * 2021-07-30 2025-02-06 Eli Lilly And Company Treatment of Hand Eczema with Baricitinib
AU2024229918A1 (en) 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500666A (ja) * 2005-07-07 2009-01-08 トムソン ライセンシング 対応スタンドを備えたフラット画面ディスプレイシステム
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
SI2432472T1 (sl) * 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
JP6427497B2 (ja) * 2013-10-21 2018-11-21 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CA2991020A1 (en) 2015-07-07 2017-01-12 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof

Also Published As

Publication number Publication date
AU2017380213A1 (en) 2019-05-23
IL267393A (en) 2019-08-29
US20200017527A1 (en) 2020-01-16
AU2017380213B2 (en) 2022-01-06
EP3559003A1 (en) 2019-10-30
TWI822666B (zh) 2023-11-21
JP2020502224A (ja) 2020-01-23
KR102788829B1 (ko) 2025-03-31
JP2023024729A (ja) 2023-02-16
MX2019007462A (es) 2019-08-29
CN110325536A (zh) 2019-10-11
IL267393B1 (en) 2023-03-01
CA3044771A1 (en) 2018-06-28
ES2926986T3 (es) 2022-10-31
BR112019012210A2 (pt) 2019-11-12
TW201829423A (zh) 2018-08-16
RU2019122566A3 (https=) 2021-12-22
IL267393B2 (en) 2023-07-01
WO2018117153A1 (en) 2018-06-28
MX386181B (es) 2025-03-18
EP3559003B1 (en) 2022-08-24
US11339181B2 (en) 2022-05-24
JP2024161449A (ja) 2024-11-19
RU2019122566A (ru) 2021-01-22
KR20190092440A (ko) 2019-08-07

Similar Documents

Publication Publication Date Title
KR102788829B1 (ko) 야누스 키나제 억제제의 결정질 형태
KR102523564B1 (ko) Jak 저해제를 제조하기 위한 피롤로피리미딘 결정
US11572365B2 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
CA2984724A1 (en) Crystal of uracil compound
CA2926845C (en) Salt and crystal forms of plk-4 inhibitor
EP3670500A1 (en) Chemical compound, pharmaceutical composition thereof, and use and application thereof
EA032872B1 (ru) Макроциклические ингибиторы rip2-киназы
US8722863B2 (en) Solid state forms of fidaxomycin and processes for preparation thereof
WO2022049253A1 (en) Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
KR20250038235A (ko) 고체 형태의 jak 억제제 및 이의 제조 공정
US20240391902A1 (en) Crystalline Form of Compound
US20220162185A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
EP3747871A1 (en) Crystal form of urate transporter 1 inhibitor and preparation method and use thereof
US20230192710A1 (en) Jak inhibitor compound and use thereof
KR20150129698A (ko) 피롤리딘-3-일 아세트산 유도체의 염 및 그의 결정
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
AU2023204840A1 (en) Carbonyl bridged heterocyclic compound, and composition and application thereof
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
HK40050819A (en) Ebna1 inhibitor crystalline forms, and methods of preparing and using same
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination